Company: CLX
Filing Date: 2025-10-07
Form Type: DEF 14A
Source: 0001552781-25-000311
Chunk: 71

Company: CLOROX CO /DE/
Filing Date: 2025-10-07
Form: DEF 14A
Chunk 71
---
 to allow for changes in the Company’s business and related       
 requirements. If such changes were to occur, the Company believes its exposure could differ from the amounts listed above. Any       
 amounts reflected in the consolidated balance sheets as Accounts payable and accrued liabilities are excluded from the table above,  
 as they are short-term in nature and expected to be paid within one year.                                                            |

| (2) | These                                                                                            
 amounts represent expected payments through 2035. Based on the accounting rules for nonqualified 
 retirement income and retirement health care plans, the liabilities reflected in the Company’s   
 consolidated balance sheets differ from these expected future payments. Refer to the Notes       
 to Consolidated Financial Statements for further details.                                        |

| (3) | The                                                                                             
 Company has a venture agreement with P&G for the Company’s Glad bags and wraps                  
 business (the Venture Agreement). As of June 30, 2025, P&G had a 20% interest in the            
 venture. Upon termination of the agreement in January 2026, the Company is required to purchase 
 P&G’s 20% interest for cash at fair value as established by predetermined valuation             
 procedures. Refer to the Notes to Consolidated Financial Statements for further details.        |

| (4) | Includes                                                                                        
 contracted spend through fiscal year 2026 related to the digital capabilities and productivity  
 enhancements investment, which is expected to be funded through cash generated from operations. |

Contingencies A summary of contingencies is contained in the Notes to Consolidated Financial Statements and is incorporated herein by reference. Quantitative and Qualitative Disclosures About Market Risk As a multinational company, the Company is exposed to the impact of changes in commodity prices, foreign currency fluctuations, interest-rate risk and other types of market risk. In the normal course of business, where available at a reasonable cost, the Company manages its exposure to market risk using contractual agreements and a variety of derivative instruments. The Company’s objective in managing its exposure to market risk is to limit the impact of fluctuations on earnings and cash flow through the use of derivative instruments, including exchange-traded futures and options contracts and over-the-counter swaps and forward purchase contracts. Over-the-counter derivative contracts are entered into for non-trading purposes with major credit-worthy institutions, thereby decreasing the risk of credit loss. The Company uses different methodologies, when necessary, to estimate the fair value of its derivative contracts. The estimated fair values of the majority of the Company’s contracts are based on quoted market prices, exchange-traded market prices or broker